 TRACON Pharmaceuticals NASDAQ:TCON Inc rounded out the second quarter with a strong cash runway to carry out key trials and continue hitting significant milestones. The San Diego, Califoria-based clinical stage biopharma company reported cash and cash equivalents of US13.6 million as of June 30 2022, compared to 24.1 million at the end of December 2021. 